Zacks Investment Research
14 Aug 2026, 14:41 UTC · 17h ago
Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
14 Aug 2026, 14:41 UTC · 17h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
BioMarin Pharmaceutical (BMRN) currently holds a Zacks Rank of #2 (Buy) and is outperforming the Medical sector with a year-to-date return of 15.3% compared to the sector average of 3%. — Positive analyst ranking and strong relative momentum typically attract short-term buying interest.
+0.30Cardinal Health (CAH) holds a Zacks Rank of #2 (Buy) and has seen its consensus EPS estimate for the current year increase by 4.6% over the last three months. — Upward earnings revisions are a strong signal for stock price appreciation.
+0.20The Zacks Consensus Estimate for BioMarin Pharmaceutical's full-year earnings has moved 0.4% higher over the past quarter. — A slight increase in earnings estimates suggests a marginally improving outlook, though the magnitude is small.
+0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The company has a Zacks Rank of #2 (Buy), improving earnings estimates, and is significantly outperforming its sector.
The company has a Zacks Rank of #2 (Buy), increasing EPS estimates, and has outperformed the medical sector.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
7h ago
